Droxidopa
Primary Autonomic Failure
Vanderbilt University Medical CenterSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Primary Autonomic Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Midodrine Vanderbilt University Medical Center | Phase 1 | CCC |
Ampreloxetine Theravance Biopharma | Phase 3 | CCC |
TRIMETAPHAN Vanderbilt University | Phase 1 | CC |
(1S,2S)-(+)-PSEUDOEPHEDRINE Vanderbilt University | Phase 1 | CC |
FDOPA Daniel Claassen | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Droxidopa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →